Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder
- PMID: 28335622
- PMCID: PMC5453828
- DOI: 10.1176/appi.ajp.2016.16050518
Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder
Erratum in
-
CORRECTIONS.Am J Psychiatry. 2017 Jun 1;174(6):604. doi: 10.1176/appi.ajp.2017.1746correction3. Am J Psychiatry. 2017. PMID: 28565951 No abstract available.
Abstract
Objective: The purpose of this article was to inform the first-line treatment choice between cognitive-behavioral therapy (CBT) or an antidepressant medication for treatment-naive adults with major depressive disorder by defining a neuroimaging biomarker that differentially identifies the outcomes of remission and treatment failure to these interventions.
Method: Functional MRI resting-state functional connectivity analyses using a bilateral subcallosal cingulate cortex (SCC) seed was applied to 122 patients from the Prediction of Remission to Individual and Combined Treatments (PReDICT) study who completed 12 weeks of randomized treatment with CBT or antidepressant medication. Of the 122 participants, 58 achieved remission (Hamilton Depression Rating Scale [HAM-D] score ≤7 at weeks 10 and 12), and 24 had treatment failure (<30% decrease from baseline in HAM-D score). A 2×2 analysis of variance using voxel-wise subsampling permutation tests compared the interaction of treatment and outcome. Receiver operating characteristic curves constructed using brain connectivity measures were used to determine possible classification rates for differential treatment outcomes.
Results: The resting-state functional connectivity of the following three regions with the SCC was differentially associated with outcomes of remission and treatment failure to CBT and antidepressant medication and survived application of the subsample permutation tests: the left anterior ventrolateral prefrontal cortex/insula, the dorsal midbrain, and the left ventromedial prefrontal cortex. Using the summed SCC functional connectivity scores for these three regions, overall classification rates of 72%-78% for remission and 75%-89% for treatment failure was demonstrated. Positive summed functional connectivity was associated with remission with CBT and treatment failure with medication, whereas negative summed functional connectivity scores were associated with remission to medication and treatment failure with CBT.
Conclusions: Imaging-based depression subtypes defined using resting-state functional connectivity differentially identified an individual's probability of remission or treatment failure with first-line treatment options for major depression. This biomarker should be explored in future research through prospective testing and as a component of multivariate treatment prediction models.
Trial registration: ClinicalTrials.gov NCT00360399.
Keywords: Antidepressants; Biological Markers; Brain Imaging Techniques; Cognitive Therapy.
Figures




Comment in
-
Getting Personalized: Brain Scan Biomarkers for Guiding Depression Interventions.Am J Psychiatry. 2017 Jun 1;174(6):503-505. doi: 10.1176/appi.ajp.2017.17030314. Am J Psychiatry. 2017. PMID: 28565957 No abstract available.
Similar articles
-
Depression-related anterior cingulate prefrontal resting state connectivity normalizes following cognitive behavioral therapy.Eur Psychiatry. 2020 Apr 14;63(1):e37. doi: 10.1192/j.eurpsy.2020.34. Eur Psychiatry. 2020. PMID: 32284075 Free PMC article.
-
Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study.Am J Psychiatry. 2017 Jun 1;174(6):546-556. doi: 10.1176/appi.ajp.2016.16050517. Epub 2017 Mar 24. Am J Psychiatry. 2017. PMID: 28335624 Free PMC article. Clinical Trial.
-
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy.Am J Psychiatry. 2023 Mar 1;180(3):218-229. doi: 10.1176/appi.ajp.21070727. Epub 2023 Jan 18. Am J Psychiatry. 2023. PMID: 36651624 Free PMC article. Clinical Trial.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
-
Predicting the treatment outcomes of major depressive disorder interventions with baseline resting-state functional connectivity: a meta-analysis.BMC Psychiatry. 2025 Apr 7;25(1):340. doi: 10.1186/s12888-025-06728-0. BMC Psychiatry. 2025. PMID: 40197372 Free PMC article.
Cited by
-
Structural brain characteristics in treatment-resistant depression: review of magnetic resonance imaging studies.BJPsych Open. 2019 Sep 2;5(5):e76. doi: 10.1192/bjo.2019.58. BJPsych Open. 2019. PMID: 31474243 Free PMC article.
-
Effects of Estradiol Therapy on Resting-State Functional Connectivity of Transgender Women After Gender-Affirming Related Gonadectomy.Front Neurosci. 2019 Aug 7;13:817. doi: 10.3389/fnins.2019.00817. eCollection 2019. Front Neurosci. 2019. PMID: 31440128 Free PMC article.
-
Rostral anterior cingulate network effective connectivity in depressed adolescents and associations with treatment response in a randomized controlled trial.Neuropsychopharmacology. 2022 May;47(6):1240-1248. doi: 10.1038/s41386-021-01214-z. Epub 2021 Nov 15. Neuropsychopharmacology. 2022. PMID: 34782701 Free PMC article. Clinical Trial.
-
Pathophysiology in cortico-amygdala circuits and excessive aversion processing: the role of oligodendrocytes and myelination.Brain Commun. 2024 Apr 18;6(3):fcae140. doi: 10.1093/braincomms/fcae140. eCollection 2024. Brain Commun. 2024. PMID: 38712320 Free PMC article. Review.
-
Dopamine Multilocus Genetic Profile, Spontaneous Activity of Left Superior Temporal Gyrus, and Early Therapeutic Effect in Major Depressive Disorder.Front Psychiatry. 2020 Dec 22;11:591407. doi: 10.3389/fpsyt.2020.591407. eCollection 2020. Front Psychiatry. 2020. PMID: 33414733 Free PMC article.
References
-
- Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for depression. Neuropsychopharmacol. 2004;29:1765–1781. - PubMed
-
- American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3. Arlington, VA: American Psychiatric Association; 2010.
-
- Craighead WE, Dunlop BW. Combination psychotherapy and antidepressant medication for depression: For whom, when and how. Ann Rev Psychol. 2014;65:267–300. - PubMed
-
- Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, Thase ME, Trivedi MH, Keller MB. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry. 2005;62:513–520. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials